Psychopharmacology

, Volume 73, Issue 4, pp 359–362

Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia

  • Chuong C. Huang
  • Richard I. H. Wang
  • Andrew Hasegawa
  • Luca Alverno
Original Investigations

DOI: 10.1007/BF00426466

Cite this article as:
Huang, C.C., Wang, R.I.H., Hasegawa, A. et al. Psychopharmacology (1981) 73: 359. doi:10.1007/BF00426466

Abstract

Thirty inpatients with evidence of tardive dyskinesia secondary to antipsychotic medications participated in this double-blind, controlled, randomized study comparing reserpine, α-methyldopa and placebo. Reserpine at doses of 0.75–1.5 mg daily, or α-methyldopa at doses of 750–1,500 mg daily, produced a statistically significant improvement in tardive dyskinesia symptomatology compared to the results obtained with placebo.

Key words

Tardive dyskinesia α-Methyldopa Reserpine 

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • Chuong C. Huang
    • 1
  • Richard I. H. Wang
    • 1
  • Andrew Hasegawa
    • 1
  • Luca Alverno
    • 1
  1. 1.Clinical Pharmacology ServiceWood Veterans Administration Medical Center and The Medical College of WisconsinMilwaukeeUSA
  2. 2.Veterans Administration Medical CenterWoodUSA

Personalised recommendations